Yazar "Gareayaghi, Nesrin" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Yayın COVID-19 geçiren, CoronaVac ve BNT162b2 aşı olan bireylerde hümoral immün yanıtın değerlendirilmesi(Harran Üniversitesi, 2022) Gareayaghi, Nesrin; Dinç, Harika Öykü; Özbey, Doğukan; Akçin, Rüveyda; Daşdemir, Ferhat; Akkuş, Seher; Eryiğit, Önder Yüksel; Kocazeybek, BekirAmaç: Günümüzde COVID-19 aşılaması ya da geçirilmiş enfeksiyon sonrasında humoral immün yanıtı değerlendirmek amacıyla pek çok immünolojik test yöntemi kullanılmaktadır. Çalışmamızda CoronaVac, veya BNT162b2 ile aşılanan ve COVID-19 geçiren kişilerde SARS-CoV-2 humoral immün yanıtı üç farklı immünolojik test yöntemiyle değerlendirmeyi amaçladık. Materyal ve metod: COVID-19 tanısı alan 30, CoronaVac aşısı olan 35 ve BNT162b2 aşısı olan 35 kişinin 28 gün sonra alınan serum örnekleri çalışmaya dahil edilmiştir. SARS-CoV 2’nin spike proteini S1 alt biriminin reseptör bağlayıcı bölgesine (RBD) karşı nötralize edici antikorlar üç farklı prensibe yönelik (CMIA, ELISA, LFA) antikor testleri ile (ARCHITECT IgG II Quant test, Abbott, USA/SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Almanya/ NeutraXpress™, JOYSBIO Biotechnology Co. Ltd., Tianjin China) çalışıldı. Verilerin istatistiksel değerlendirmesinde IBM SPSS 21.0 paket programı kullanıldı. Bulgular: Tüm olguların SARS-CoV-2 kantitatif antikor titreleri 2635,150 (391,1-8053,425) AU/mL olarak saptandı. Gruplar arasındaki istatistiksel değerlendirmede, COVID-19 geçiren ve BNT162b2 aşısı olan kişilerin SARS-CoV-2 kantitatif antikor titreleri, CoronaVac ile aşılı gruba kıyasla anlamlı olarak yüksek saptandı (p<0.001). SARS-CoV-2 nötralizan antikor inhibisyon yüzdesi tüm olgularda %88,4 (32,9-98,8) iken, COVID-19 geçiren ve BNT162b2 aşısı olanlarda anlamlı olarak yüksek saptandı (p<0.001). Lateral-flow yöntemine göre bağlanan total antikor varlığı 75 (%75) kişide pozitif olarak saptanırken, nötralizan antikor 60 (%60) kişide pozitif olarak saptandı. Sonuç: Çalışmamızın sonuçlarına göre, enfeksiyon ve aşılama sonrası SARS-CoV-2’ye spesifik humoral immün yanıtın geliştiği görülmektedir. Ayrıca, immünolojik yöntemlerle humoral immün yanıtın değerlendirilmesinde, duyarlılığı ve özgüllüğü yüksek olan testlerin tercih edilmesi gerektiğini düşünmekteyiz.Yayın Evaluation of the diagnostic performance of a SARS-CoV-2 and Influenza A/B combo rapid antigen test in respiratory samples(MPDI, 2023) Dinç, Harika Öykü; Karabulut, Nuran; Alaçam, Sema; Kırkoyun Uysal, Hayriye; Daşdemir, Ferhat Osman; Önel, Mustafa; Tuyji Tok, Yeşim; Sirekbasan, Serhat; Agaçfidan, Ali; Gareayaghi, Nesrin; Çakan, Hüseyin; Eryiğit, Önder Yüksel; Kocazeybek, BekirThis study aimed to evaluate the performance characteristics of a rapid antigen test developed to detect SARS-CoV-2 (COVID-19), influenza A virus (IAV), and influenza B virus (IBV) (flu) compared with those of the real-time reverse transcription-polymerase chain reaction (rRT-PCR) method. One hundred SARS-CoV-2, one hundred IAV, and twenty-four IBV patients whose diagnoses were confirmed by clinical and laboratory methods were included in the patient group. Seventy-six patients, who were negative for all respiratory tract viruses, were included as the control group. The Panbio™ COVID-19/Flu A&B Rapid Panel test kit was used in the assays. The sensitivity values of the kit were 97.5%, 97.9%, and 33.33% for SARS-CoV-2, IAV, and IBV, respectively, in samples with a viral load below 20 Ct values. The sensitivity values of the kit were 16.7%, 36.5%, and 11.11% for SARS-CoV-2, IAV, and IBV, respectively, in samples with a viral load above 20 Ct. The kit’s specificity was 100%. In conclusion, this kit demonstrated high sensitivity to SARS-CoV-2 and IAV for viral loads below 20 Ct values, but the sensitivity values were not compatible with PCR positivity for lower viral loads over 20 Ct values. Rapid antigen tests may be preferred as a routine screening tool in communal environments, especially in symptomatic individuals, when diagnosing SARS-CoV-2, IAV, and IBV with high caution.Yayın Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: A retrospective cohort study(Frontiers Media S. A., 2026) Kara, Zehra; Ak, Tümay; Demir, Ahmet Numan; Akçin, Rüveyda; Dinç, Harika Öykü; Taşkın, Halit Eren; Gareayaghi, Nesrin; Kocazeybek, Bekir; Yumuk, Volkan DemirhanAim: The aim of this study was to describe the frequency of post-vaccination SARS-CoV-2 infection and to compare SARS-CoV-2 IgG antibody levels between patients with severe obesity and individuals without obesity after two doses of the BNT162b2 vaccine. Methods: One hundred two consecutive patients with severe obesity seen in the obesity outpatient clinic and 54 individuals without obesity who visited a vaccination outpatient clinic were included in the study. Inactivated Severe Adult Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG levels of these two groups were measured four weeks after administration of two doses of BNT162b2 vaccine. SARS-CoV-2 infection was defined as a PCR-confirmed infection documented in hospital records during the 12-month follow-up after completion of two-dose BNT162b2 vaccination. PCR testing was performed only when participants presented to the hospital with clinical suspicion of COVID-19 and was not conducted as routine screening. Clinical characteristics, protective measures and contact history were also queried. Results: There was a statistically significant difference in SARS-CoV-2 infection rates after vaccination between the patients with severe obesity (n=28, 27%) and individuals without obesity (n=3, 5%) (p=0.001). In patients with severe obesity, SARS-CoV-2 IgG levels after BNT162b2 vaccination were lower in the group with SARS-CoV-2 infection than in the group without SARS-CoV-2 infection [2697 (1096-8955); 8103 (2208-26903) AUml, respectively] (p=0.008). The antibody levels of those with severe fatigue were lower than those without these complaints [2440 (365-4447); 8955 (2440-16317) AUml, respectively] (p=0.03). A loss of taste or smell was observed in 75% of patients with severe obesity but was not observed in individuals without obesity (p=0.03). In patients with severe obesity, those with taste/smell loss had statistically significantly lower SARS CoV-2 IgG titres than those without severe obesity [2568 (400-4830); 95(2611-16810) AUml, p: 0.02]. Multiple logistic regression analysis revealed a correlation between body mass index (BMI) and having had a SARS-CoV-2 infection after BNT162b2 vaccination (p = 0.028, Exp(B) = 1.072). There was no need for hospitalisation due to SARS-CoV-2 infection and there were no deaths in either group. Conclusion: Patients with severe obesity had higher rates of SARS-CoV-2 infection after BNT162b2 vaccination compared to individuals without obesity. SARS-CoV-2 IgG levels were lower in patients with severe obesity after BNT162b2 vaccination. Based on these findings, given the higher frequency of post-vaccination infections in the patients with severe obesity, timely booster vaccination policies may be particularly important for this population.Severe obesity, SARS-CoV-2, BNT162b2, SARS-CoV-2 IgG, breakthrough infection. Key points: The rate of SARS-CoV-2 infection after vaccination was higher in patients with severe obesity than in individuals without obesity.It has been found that antibody levels are lower in patients with severe fatigue symptoms than in patients without these symptoms.Loss of taste or smell was observed at a high rate (75%) in the group with severe obesity, but not in individuals without obesity.In this study, there were no hospitalisations or deaths after vaccination with BNT162b2 in patients with severe obesity.Body mass index (BMI) has been found to negatively affect the likelihood of contracting SARS-CoV-2 infection after receiving the BNT162b2 vaccine.In our study, we emphasise the importance of vaccination in patients with severe obesity.Yayın The role of Adenovirus-36 in adults with obesity-induced type 2 diabetes(Verlag Klinisches Labor GmbH, 2022) Tokman, Halit; Ergin, Sevgi; Sarıbaş, Suat; Dinç, Harika Öykü; Cengiz, Mahir; Yavuzer, Serap; Çizmecigil, Utku Yusuf; Önder, Nuri T.; Yılmaz, Hüseyin; Eryiğit, Önder Yüksel; Gareayaghi, Nesrin; Kocazeybek, Bekir SamiBackground: Obesity may also develop due to a viral infection caused by adenovirus 36. We aimed to detect the presence of neutralizing antibodies against Ad-36 in adult patients who developed type 2 diabetes due to obesity (BMI ≥ 30 kg/m2). Methods: The patient group (PG) was composed of 80 obese people with type 2 diabetes, the patient control group (PCG) was composed of 40 non-obese people with type 2 diabetes, and the healthy control group (HCG) was composed of 40 non-obese people without type 1 or type 2 diabetes in this case-control study. The presence of Ad-36 neutralizing antibodies was studied by serum neutralization assay. Results: A significant difference was found between the PG and HCG in terms of Ad-36 antibody positivity (p < 0.0001) but no significant difference was detected between the PG and the PCG (p > 0.05). BMI, serum leptin, adiponectin, and triglyceride levels were significantly higher in the PG (p < 0.05). Conversely, TNF-α and IL-6 levels were significantly lower in the PG (p < 0.0001). When the two groups were compared, the mean levels of total cholesterol and LDL in the PG were found to be high, although not significant (p > 0.05). In type 2 diabetes patients (n = 120), age, BMI, HDL, LDL, triglyceride, total cholesterol, Ad-36 presence, leptin, adiponectin, TNF-α, and IL-6 parameters were taken as independent variables for logistic regression. While BMIs was found to be significant (odds ration [OR] = 2.358; p = 0.0001, 95% Cl 1.507 - 3.690, Ad-36 presence was found to be a significant (OR = 27.352; p = 0.003, 95% Cl 3.157 - 236.961). Our study showed that BMI and Ad-36 increase type 2 diabetes risk by 2.3 and 27.3-fold in the PG and PCG (type 2 diabetes patients) versus the HCG. There was also a significant difference between PCG and HCG. Conclusions: We suggest that Ad-36 seropositivity is also a risk factor for the development of type 2 diabetes independent of being obese. © 2022 Verlag Klinisches Labor GmbH. All rights reserved.
